Lekoklar (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This blocks the translocation step of peptide chain elongation, halting bacterial growth and resulting in a bacteriostatic effect against susceptible organisms.

The dosage of Lekoklar is determined by the prescribing clinician based on the infection being treated, patient age, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and the label directions.

The safety of clarithromycin in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks before prescribing to pregnant or nursing individuals. Patients should discuss any concerns with their prescriber.

To request Lekoklar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lekoklar (clarithromycin) shares the macrolide class with drugs like azithromycin and erythromycin. Compared with azithromycin, clarithromycin generally has a broader spectrum against certain Gram‑positive organisms and a higher potential for drug‑drug interactions due to CYP3A4 inhibition. Choice of agent depends on the infection, susceptibility patterns, and patient-specific factors.

Lekoklar should be stored at temperatures below 25°C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Lekoklar is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a full glass of water. Patients should not crush or chew the tablet unless specifically instructed.

Serious adverse reactions to Lekoklar can include hepatotoxicity, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they experience symptoms like jaundice, irregular heartbeat, severe rash, or persistent diarrhea.

Lekoklar is contraindicated in individuals with a known hypersensitivity to clarithromycin, other macrolides, or any of the tablet’s excipients. It should also be avoided in patients with a history of significant QT prolongation, severe hepatic impairment, or those taking medications that have a high risk of dangerous interactions without appropriate monitoring.